Novartis announced longer-term analyses of both ELIANA and JULIET, the pivotal clinical trials of Kymriah (tisagenlecleucel) in children and young adult patients with relapsed or refractory (r/r) acute lymphoblastic leukemia (ALL) and adult patients with r/r diffuse large B-cell lymphoma (DLBCL), respectively.

Updated Phase 3 ALCYONE results, featured as oral presentation at ASH 2018, show improved progression-free survival in newly diagnosed patients

Research from the American Cancer Society shows lung cancer rates in Asian-Americans vary among subgroups.

Leading Provider of Post-Acute Care Forms Component Patient Safety Organization

To Meet Burgeoning Need, RCA Adds a Third Center in New Jersey for Life-Saving Addiction Treatment Services